Abstract
The clinical effects of bifemelane hydrochloride on hearing loss were investigated in 16 patients with Meniere's disease (27 ears). The dosage was 150 mg of bifemelane hydrochloride (Alnert(R)) daily for 8 weeks to 10 months. The control group consisted of 26 patients with Meniere's disease (40 ears).1. Improvement of the hearing level was seen in 44.4 % of the ears of those treated with bifemelane hydrochloride at the 8 week point, when all subjects were examined. Great improvement was noted in 7.4% of the ears, moderate improvement in 3.7%6, and slight improvement in 33.3%. These results were significantly higher than those of the control group. Moreover, some level of improvement was seen in a total of 60.0% of 15 ears in 10 patients who received bifemelane for more than 5 month.2. The degree of improvement in hearing levels were greater in those with less than 60 dB hearing than in those with 60 dB and over hearing at the time of the 8 week examination.3. The efficacy of bifemalane hydrochloride was unrelated to the patient's age.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
